Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Authors
Keywords
-
Journal
OncoImmunology
Volume 8, Issue 8, Pages 1615817
Publisher
Informa UK Limited
Online
2019-06-03
DOI
10.1080/2162402x.2019.1615817
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immune contexture of hepatocellular carcinoma predicts clinical outcome
- (2018) Friedrich Foerster et al. Scientific Reports
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
- (2016) Markus Moehler et al. EUROPEAN JOURNAL OF CANCER
- Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
- (2015) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Viruses for Tumor Therapy
- (2014) John Bell et al. Cell Host & Microbe
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- HCC therapies—lessons learned
- (2014) Marcus-Alexander Wörns et al. Nature Reviews Gastroenterology & Hepatology
- Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
- (2014) Markus Moehler et al. Frontiers in Oncology
- Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
- (2013) C. J. Breitbach et al. CANCER RESEARCH
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
- (2013) R. Lencioni CLINICAL CANCER RESEARCH
- High Procedure Volume Is Strongly Associated With Improved Survival After Lung Cancer Surgery
- (2013) Margreet Lüchtenborg et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2012) EUROPEAN JOURNAL OF CANCER
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1
- (2012) Maike Sieben et al. INTERNATIONAL JOURNAL OF CANCER
- First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study
- (2012) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- First Report of the Cereal Cyst Nematode Heterodera latipons on Wheat in Morocco
- (2012) F. Mokrini et al. PLANT DISEASE
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
- (2011) Kelley A Parato et al. MOLECULAR THERAPY
- Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells
- (2011) Xiangxuan Zhao et al. PLoS One
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
- (2008) Eugen Koren et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
- (2008) Ta-Chiang Liu et al. MOLECULAR THERAPY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation